Regulatory approval

Published by the Health Canada.

Health Canada approved dasatinib for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

This is written in the approval document as:

SPRYCEL (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

Citation

Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080799.PDF. Revised June 2025. Accessed April 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HC (1) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib